Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CBLC |
| Gene Name: | CBLC |
| Protein Full Name: | Signal transduction protein CBL-C |
| Alias: | Cas-Br-M (murine) ecotropic retroviral transforming sequence c; CBL3; CBL-3; CBLC; CBL-SL; RING finger protein 57; RNF57; SH3-binding protein CBL-C |
| Mass (Da): | 52456 |
| Number AA: | 474 |
| UniProt ID: | Q9ULV8 |
| Locus ID: | 23624 |
| COSMIC ID: | CBLC |
| Gene location on chromosome: | 19q13.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 21166 |
| Percent of cancer specimens with mutations: | 0.43 |
| Normal role description: | CBLC is a ubiquitously expressed cytoplasmic protein of molecular weight 52.5 kDa. CBLC is a substrate targetted for phosphorylation by receptor tyrosine kinases. Within the EGF receptor signalling pathway CBLC is recruited to the EGF receptor through a phosphotyrosine binding domain and inhibits EGF mediated activation of MAP kinase. CBLC is also a known negative regulator of HGF/Met sigalling and dysfunction in CBLC may lead to Met-mediated cancer development |
| Commentary on involvement of protein in cancer: | Two mutations in ovary tissue were of unknown histology, both were mis-sense mutations |